Mobile HIV Screening in Cape Town, South Africa: Clinical Impact, Cost and Cost-effectiveness
Overview
Authors
Affiliations
Background: Mobile HIV screening may facilitate early HIV diagnosis. Our objective was to examine the cost-effectiveness of adding a mobile screening unit to current medical facility-based HIV testing in Cape Town, South Africa.
Methods And Findings: We used the Cost Effectiveness of Preventing AIDS Complications International (CEPAC-I) computer simulation model to evaluate two HIV screening strategies in Cape Town: 1) medical facility-based testing (the current standard of care) and 2) addition of a mobile HIV-testing unit intervention in the same community. Baseline input parameters were derived from a Cape Town-based mobile unit that tested 18,870 individuals over 2 years: prevalence of previously undiagnosed HIV (6.6%), mean CD4 count at diagnosis (males 423/µL, females 516/µL), CD4 count-dependent linkage to care rates (males 31%-58%, females 49%-58%), mobile unit intervention cost (includes acquisition, operation and HIV test costs, $29.30 per negative result and $31.30 per positive result). We conducted extensive sensitivity analyses to evaluate input uncertainty. Model outcomes included site of HIV diagnosis, life expectancy, medical costs, and the incremental cost-effectiveness ratio (ICER) of the intervention compared to medical facility-based testing. We considered the intervention to be "very cost-effective" when the ICER was less than South Africa's annual per capita Gross Domestic Product (GDP) ($8,200 in 2012). We projected that, with medical facility-based testing, the discounted (undiscounted) HIV-infected population life expectancy was 132.2 (197.7) months; this increased to 140.7 (211.7) months with the addition of the mobile unit. The ICER for the mobile unit was $2,400/year of life saved (YLS). Results were most sensitive to the previously undiagnosed HIV prevalence, linkage to care rates, and frequency of HIV testing at medical facilities.
Conclusion: The addition of mobile HIV screening to current testing programs can improve survival and be very cost-effective in South Africa and other resource-limited settings, and should be a priority.
Abou Jaoude G, Namakoola I, Aikaeli F, Kimaro G, Moyo F, Kasujja F NIHR Open Res. 2025; 4:80.
PMID: 40027170 PMC: 11868744. DOI: 10.3310/nihropenres.13794.2.
DCouto H, Thielking A, Sewpaul R, Levy D, Rigotti N, Chrysanthopoulou S BMJ Glob Health. 2024; 9(12).
PMID: 39675836 PMC: 11647297. DOI: 10.1136/bmjgh-2024-017049.
Relationship between universal health insurance benefits and prostate cancer mortality in Colombia.
Mejia E, Lewis A, Garces-Palacio I, Hernandez D, Chamberlain R, Soliman A BMC Public Health. 2024; 24(1):2667.
PMID: 39350101 PMC: 11441010. DOI: 10.1186/s12889-024-20117-4.
Costs of HIV testing services in sub-Saharan Africa: a systematic literature review.
Ahmed N, Ong J, McGee K, dElbee M, Johnson C, Cambiano V BMC Infect Dis. 2024; 22(Suppl 1):980.
PMID: 39192180 PMC: 11348535. DOI: 10.1186/s12879-024-09770-7.
Thielking A, Fitzmaurice K, Sewpaul R, Chrysanthopoulou S, Dike L, Levy D J Int AIDS Soc. 2024; 27(6):e26315.
PMID: 38924347 PMC: 11197963. DOI: 10.1002/jia2.26315.